is predicted to increase the exposure to imatinib.
Study → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to increase the risk of toxicity when
given with irinotecan. Avoid.oStudy → Also see TABLE 15
▶ Idelalisib is predicted to increase the exposure to ivabradine.
▶ Idelalisib is predicted to increase the exposure to ivacaftor.
Adjust ivacaftor p. 293 or lumacaftor with ivacaftor p. 294 or
tezacaftor with ivacaftor p. 295 dose with potent inhibitors of
▶ Idelalisib is predicted to increase the exposure to lapatinib.
▶ Idelalisib is predicted to markedly increase the exposure to
▶ Idelalisib is predicted to increase the exposure to lurasidone.
is predicted to increase the exposure to macitentan.
▶ Idelalisib markedly increases the exposure to maraviroc.
▶ Idelalisib is predicted to markedly to very markedly increase
the exposure to midazolam. Avoid or adjust dose.rStudy
▶ Idelalisib is predicted to very markedly increase the exposure
to midostaurin. Avoid or monitor for toxicity.rStudy
▶ Idelalisib is predicted to increase the exposure to mirabegron.
Adjust mirabegron dose in hepatic and renal impairment,
is predicted to increase the exposure to mirtazapine.
▶ Mitotane is predicted to decrease the exposure to idelalisib.
Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to increase the exposure to modafinil.
▶ Idelalisib is predicted to increase the exposure to monoclonal
antibodies (trastuzumab emtansine). Avoid.rTheoretical →
▶ Idelalisib is predicted to markedly increase the exposure to
is predicted to increase the exposure to netupitant.
▶ Nevirapine is predicted to decrease the exposure to idelalisib.
▶ Idelalisib is predicted to moderately increase the exposure to
nilotinib. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to increase the exposure to nitisinone.
▶ Idelalisib is predicted to increase the exposure to olaparib.
Avoid potent inhibitors of CYP3A4 or adjust olaparib dose,
p. 1005.oStudy → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to increase the exposure to opioids
(alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil).
Monitor and adjust dose.rStudy
▶ Idelalisib is predicted to increase the exposure to opioids
▶ Idelalisib is predicted to increase the exposure to ospemifene.
Avoid in poor CYP2C9 metabolisers.oStudy
▶ Idelalisib is predicted to increase the exposure to oxybutynin.
▶ Idelalisib is predicted to increase the exposure to palbociclib.
Avoid or adjust palbociclib dose, p. 992.rStudy
▶ Idelalisib is predicted to increase the exposure to
panobinostat. Adjust panobinostat dose; in hepatic
impairment avoid, p. 936.oStudy → Also see TABLE 15
▶ Paritaprevir is predicted to increase the exposure to idelalisib.
▶ Idelalisib is predicted to increase the exposure to pazopanib.
Avoid or adjust pazopanib dose, p. 993.oStudy → Also see
▶ Idelalisib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid.
▶ Idelalisib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (sildenafil). Avoid potent
inhibitors of CYP3A4 or adjust
▶ Idelalisib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (tadalafil). Use with caution
▶ Idelalisib is predicted to increase the exposure to pimozide.
1470 Idelalisib — Idelalisib BNF 78
▶ Idelalisib is predicted to slightly increase the exposure to
▶ Idelalisib is predicted to increase the exposure to quetiapine.
▶ Idelalisib is predicted to increase the exposure to ranolazine.
▶ Idelalisib is predicted to increase the exposure to reboxetine.
▶ Idelalisib is predicted to increase the exposure to regorafenib.
Avoid.oStudy → Also see TABLE 15 p. 1378
is predicted to increase the exposure to repaglinide.
▶ Idelalisib is predicted to increase the exposure to retinoids
Avoid or adjust ribociclib dose, p. 997.oStudy
▶ Rifampicin is predicted to decrease the exposure to idelalisib.
▶ Idelalisib is predicted to increase the exposure to risperidone.
▶ Idelalisib is predicted to increase the exposure to ruxolitinib.
Adjust dose and monitor side effects.oStudy → Also see
is predicted to increase the exposure to saxagliptin.
▶ Idelalisib is predicted to increase the concentration of
▶ Idelalisib is predicted to increase the exposure to solifenacin.
Adjust solifenacin p. 779 or tamsulosin with solifenacin p. 786
dose; avoid in hepatic and renal impairment.rStudy
▶ Idelalisib is predicted to moderately increase the exposure to
SSRIs (dapoxetine). Avoid potent inhibitors of CYP3A4 or
adjust dapoxetine dose, p. 821.rStudy
▶ St John’s Wort is predicted to decrease the exposure to
idelalisib. Avoid.oTheoretical
▶ Idelalisib is predicted to increase the exposure to statins
(atorvastatin). Avoid or adjust dose and monitor
▶ Idelalisib is predicted to increase the exposure to statins
▶ Idelalisib is predicted to slightly increase the exposure to
sunitinib dose, p. 999.o ▶ Idelalisib is predicted to increase the concentration of
tacrolimus. Monitor and adjust dose.rStudy
▶ Idelalisib is predicted to increase the exposure to taxanes
(cabazitaxel). Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to moderately increase the exposure to
taxanes (docetaxel). Avoid or adjust dose.rStudy → Also
▶ Idelalisib is predicted to increase the exposure to taxanes
(paclitaxel).rTheoretical → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to increase the concentration of
temsirolimus. Avoid.rTheoretical → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to increase the exposure to tezacaftor.
Adjust tezacaftor with ivacaftor p. 295 dose with potent
▶ Idelalisib is predicted to markedly increase the exposure to
▶ Idelalisib is predicted to increase the exposure to tofacitinib.
Adjust tofacitinib dose, p. 1105.oStudy
▶ Idelalisib is predicted to increase the exposure to tolterodine.
▶ Idelalisib is predicted to increase the exposure to tolvaptan.
Manufacturer advises caution or adjust tolvaptan dose with
potent inhibitors of CYP3A4, p. 669.rStudy
is predicted to increase the exposure to toremifene.
▶ Idelalisib is predicted to increase the exposure to trabectedin.
Avoid or adjust dose.rTheoretical → Also see TABLE 15
▶ Idelalisib is predicted to moderately increase the exposure to
trazodone. Avoid or adjust dose.oStudy
▶ Idelalisib is predicted to increase the exposure to ulipristal.
Avoid if used for uterine fibroids.rStudy
is predicted to increase the exposure to vemurafenib.
▶ Idelalisib is predicted to increase the exposure to venetoclax.
Avoid or adjust dose—consult product literature.rStudy
is predicted to increase the exposure to venlafaxine.
▶ Idelalisib is predicted to increase the exposure to vinca
alkaloids.rTheoretical → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to increase the exposure to vitamin D
substances (paricalcitol).oStudy
▶ Idelalisib is predicted to increase the exposure to zopiclone.
Ifosfamide → see alkylating agents
Iloprost → see TABLE 4 p. 1375 (antiplatelet effects)
Imatinib → see TABLE 15 p. 1378 (myelosuppression)
is predicted to increase the exposure to abemaciclib.
▶ Imatinib is predicted to increase the exposure to aldosterone
(eplerenone). Adjust eplerenone dose, p. 193.r
▶ Imatinib is predicted to increase the exposure to alpha blockers
is predicted to increase the exposure to alprazolam.
▶ Imatinib is predicted to increase the exposure to
antiarrhythmics (dronedarone).rTheoretical
▶ Imatinib is predicted to increase the exposure to
(propafenone). Monitor and adjust dose.
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Antiepileptics (oxcarbazepine) decrease the exposure to
▶ Antifungals, azoles (fluconazole, posaconazole) are predicted to
increase the exposure to imatinib.oTheoretical
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to imatinib.oStudy
▶ Imatinib is predicted to decrease the exposure to antifungals,
azoles (isavuconazole).oTheoretical
▶ Imatinib is predicted to increase the exposure to antihistamines,
non-sedating (mizolastine).rTheoretical
▶ Imatinib is predicted to increase the exposure to antihistamines,
non-sedating (rupatadine). Avoid.oStudy
▶ Imatinib is predicted to increase the concentration of
antimalarials (piperaquine).rTheoretical
is predicted to increase the exposure to imatinib.
▶ Asparaginase is predicted to increase the risk of hepatotoxicity
when given with imatinib.rTheoretical → Also see TABLE 15
is predicted to increase the exposure to axitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the exposure to bedaquiline.
Avoid prolonged use.nTheoretical
is predicted to decrease the exposure to imatinib.
▶ Imatinib is predicted to increase the exposure to bosutinib.
Avoid or adjust dose.rTheoretical → Also see TABLE 15
▶ Imatinib is predicted to increase the exposure to buspirone.
Use with caution and adjust dose.oStudy
is predicted to increase the exposure to cabozantinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to imatinib.oTheoretical
▶ Imatinib is predicted to increase the exposure to calcium
channel blockers (amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
BNF 78 Idelalisib — Imatinib 1471
▶ Imatinib is predicted to increase the exposure to cariprazine.
is predicted to increase the exposure to ceritinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the concentration of
is predicted to increase the exposure to imatinib.
is predicted to increase the exposure to cobimetinib.
▶ Imatinib is predicted to increase the exposure to colchicine.
Adjust colchicine dose with moderate inhibitors of CYP3A4,
▶ Imatinib is predicted to increase the exposure to corticosteroids
(methylprednisolone). Monitor and adjust dose.oStudy
▶ Imatinib is predicted to increase the risk of bleeding events
when given with coumarins.rTheoretical
▶ Crisantaspase is predicted to increase the risk of
hepatotoxicity when given with imatinib.rTheoretical →
▶ Imatinib is predicted to slightly increase the exposure to
is predicted to increase the exposure to dasatinib.
Study → Also see TABLE 15 p. 1378
▶ Imatinib increases the risk of QT-prolongation when given
with domperidone. Avoid.rStudy
▶ Imatinib is predicted to increase the exposure to dopamine
receptor agonists (bromocriptine).rTheoretical
▶ Imatinib is predicted to increase the concentration of
dopamine receptor agonists (cabergoline).oAnecdotal
▶ Imatinib is predicted to moderately increase the exposure to
is predicted to decrease the exposure to imatinib.
▶ Imatinib is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Imatinib is predicted to moderately increase the exposure to
▶ Enzalutamide is predicted to decrease the exposure to
▶ Imatinib is predicted to increase the risk of ergotism when
given with ergometrine.rTheoretical
▶ Imatinib is predicted to increase the risk of ergotism when
given with ergotamine.rTheoretical
is predicted to increase the exposure to erlotinib.
▶ Imatinib is predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy → Also see
▶ Imatinib is predicted to increase the exposure to fesoterodine.
Adjust fesoterodine dose with moderate inhibitors of CYP3A4
in hepatic and renal impairment, p. 777.nStudy
is predicted to increase the exposure to gefitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Grapefruit juice is predicted to increase the exposure to
▶ Imatinib is predicted to increase the concentration of
guanfacine. Adjust guanfacine dose, p. 352.oTheoretical
▶ HIV-protease inhibitors are predicted to increase the exposure
▶ Imatinib is predicted to increase the exposure to ibrutinib.
Adjust ibrutinib dose with moderate inhibitors of CYP3A4,
p. 983.rStudy → Also see TABLE 15 p. 1378
is predicted to increase the exposure to imatinib.
Study → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the exposure to ivabradine.
Adjust ivabradine dose, p. 211.rTheoretical
▶ Imatinib is predicted to increase the exposure to ivacaftor.
Adjust ivacaftor p. 293 or tezacaftor with ivacaftor p. 295 dose
with moderate inhibitors of CYP3A4.rStudy
is predicted to increase the exposure to lapatinib.
▶ Imatinib is predicted to increase the exposure to lomitapide.
▶ Imatinib is predicted to increase the exposure to lurasidone.
Adjust lurasidone dose, p. 398.oStudy
▶ Macrolides (clarithromycin) are predicted to increase the
▶ Macrolides (erythromycin) are predicted to increase the
exposure to imatinib.oTheoretical
▶ Imatinib is predicted to increase the exposure to midazolam.
Monitor side effects and adjust dose.rStudy
is predicted to increase the exposure to midostaurin.
▶ Mitotane is predicted to decrease the exposure to imatinib.
Avoid.oStudy → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the exposure to naloxegol.
naloxegol dose and monitor side effects, p. 65.o ▶ Netupitant
is predicted to increase the exposure to imatinib.
is predicted to decrease the exposure to imatinib.
▶ Imatinib is predicted to increase the exposure to olaparib.
Avoid moderate inhibitors of CYP3A4 or adjust olaparib dose,
p. 1005.oTheoretical → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the exposure to opioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
▶ Imatinib is predicted to increase the exposure to opioids
(methadone, sufentanil).oTheoretical
▶ Imatinib is predicted to increase the exposure to oxybutynin.
▶ Imatinib increases the risk of hepatotoxicity when given with
is predicted to increase the exposure to pazopanib.
Theoretical → Also see TABLE 15 p. 1378
▶ Pegaspargase is predicted to increase the risk of
hepatotoxicity when given with imatinib.rTheoretical →
▶ Imatinib is predicted to increase the risk of bleeding events
when given with phenindione.rTheoretical
▶ Imatinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil
▶ Imatinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (sildenafil). Monitor or
adjust sildenafil dose with moderate inhibitors of CYP3A4,
▶ Imatinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (tadalafil).rTheoretical
▶ Imatinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors
▶ Imatinib is predicted to increase the exposure to pimozide.
▶ Imatinib is predicted to increase the exposure to quetiapine.
is predicted to increase the exposure to ranolazine.
is predicted to increase the exposure to ribociclib.
▶ Rifampicin is predicted to decrease the exposure to imatinib.
is predicted to increase the exposure to ruxolitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the exposure to saxagliptin.
▶ Imatinib increases the concentration of sirolimus. Monitor and
▶ Imatinib is predicted to increase the exposure to SSRIs
(dapoxetine). Adjust dapoxetine dose with moderate inhibitors
of CYP3A4, p. 821.oTheoretical
▶ St John’s Wort is predicted to decrease the exposure to
▶ Imatinib is predicted to increase the exposure to statins
(atorvastatin). Monitor and adjust dose.rStudy
1472 Imatinib — Imatinib BNF 78
▶ Imatinib is predicted to increase the exposure to statins
(simvastatin). Use with caution and adjust simvastatin dose,
is predicted to increase the exposure to sunitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the concentration of
▶ Imatinib is predicted to increase the exposure to taxanes
(cabazitaxel).oTheoretical → Also see TABLE 15 p. 1378
▶ Tedizolid is predicted to increase the exposure to imatinib.
▶ Imatinib is predicted to increase the concentration of
temsirolimus.oTheoretical → Also see TABLE 15 p. 1378
▶ Imatinib is predicted to increase the exposure to tezacaftor.
Adjust tezacaftor with ivacaftor p. 295 dose with moderate
▶ Imatinib given with a potent CYP2C19 inhibitor is predicted to
increase the exposure to tofacitinib. Adjust tofacitinib dose,
▶ Imatinib is predicted to increase the exposure to tolterodine.
▶ Imatinib is predicted to increase the exposure to tolvaptan.
Manufacturer advises caution or adjust tolvaptan dose with
No comments:
Post a Comment
اكتب تعليق حول الموضوع